Home ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia

ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia

Find out more …

General Information
of the Company
Financial and
Economic Information
Corporate Governance
Information for Investors
Contact

Español

Read time: 0 mins

https://rovi.es/sites/default/files/PR_Doria_0.pdf

Year:

2019

ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia

A) FORM FOR EXERCISE OF RIGHT OF ACCESS

Particulars of applicant:

He/she requests:

B) FORM FOR EXERCISE OF RIGHT TO RECTIFICATION

Particulars of applicant:

He/she requests:

C) FORM FOR EXERCISE OF THE RIGHT TO ERASURE

Particulars of applicant:

He/she requests:

Reasons for erasure:

D) FORM FOR EXERCISE OF THE RIGHT TO RESTRICTION OF PROCESSING

Particulars of applicant:

He/she requests:

E) FORM FOR EXERCISE OF THE RIGHT TO DATA PORTABILITY

Particulars of applicant:

He/she requests:

F) FORM FOR EXERCISE OF THE RIGHT TO OBJECT

Particulars of applicant:

He/she requests: